瑞士AI药物试验初创公司获Spotify投资方Creandum注资苏黎世，10月27日——瑞士AI初创公司Atlast Bio利用虚拟患者进行药物试验，该公司周二表示，已获得1250万美元融资，由瑞典风险投资公司Creandum领投，后者是Spotify和Trade Republic的早期投资方。
Swiss AI drug trial start-up receives funding from Spotify-backer Creandum ZURICH, Oct 27 - Swiss AI start-up Atlast Bio, which runs drug trials on virtual patients, has received $12.5 million in funding led by Swedish venture capital firm Creandum, an early backer of Spotify and Trade Republic, the company said on Tuesday. • Atlas Bio is aiming to replace Phase II drug trials, which it says cost more than $100 million, take two to three years and see about 70% of drugs fail at that stage
- Atlas Bio旨在取代II期药物试验，该公司称这类试验耗资超过1亿美元、耗时两到三年，且约70%的药物在这一阶段失败
• An AI foundation model, trained on about two million human RNA readouts, would replace these and animal testing with 12-week simulations, the company said
- 该公司表示，一个基于约200万份人类RNA读数训练而成的AI基础模型，将通过为期12周的模拟来取代这些试验和动物测试
• Virtual trials can also evaluate drugs across multiple diseases simultaneously, something not feasible in conventional clinical trials, Atlas Bio added • Atlas Bio was founded by former Google employees alongside AI and pharmaceutical specialists